Announcing Enjamb's backing by Y Combinator to build the agentic workspace for drug programs.Clinical development
Enjamb agents synthesize clinical precedent, identify endpoints and patient populations, draft protocol concepts, and carry the rationale into SAPs and review-ready materials.
Workspace prompt
Design a Phase II trial concept with endpoint, population, comparator, and SAP rationale.
Agent response
Enjamb reviews precedent, proposes design options, drafts protocol language, and prepares the evidence behind the strategy.
Execution runbook
Enjamb turns an open-ended program request into a reviewable chain of evidence, analysis, drafting, and audit.
Agents extract comparator choices, endpoints, inclusion criteria, safety monitoring, and design tradeoffs from prior studies.
The workflow proposes arms, populations, endpoints, visit schedules, and analysis considerations with pros and cons.
Agents turn approved choices into protocol concepts, endpoint rationale, SAP outlines, and review notes.
Audit agents look for amendment risks, evidence gaps, inconsistent assumptions, and unsupported design claims.
Use case workflow
Clinical evidence
Agents compare prior trials, labels, publications, endpoints, eligibility criteria, and safety signals so design choices are grounded in the best available context.
Trial documents
Protocol concepts, endpoint rationale, analysis considerations, and SAP sections can be generated from the same evidence base and reviewed in the workspace.
Agent team
Compares trials, labels, endpoints, eligibility criteria, and outcomes.
Creates protocol concepts and design alternatives from evidence.
Connects endpoints and populations to analysis strategy.
Flags amendment risk, weak rationale, and operational ambiguity.
Artifacts produced
Review safeguards
Outcomes
The goal is not more documents. It is a faster, more traceable way to move program work into review.
Sharper endpoint selection
Better population and comparator rationale
Fewer late design surprises